See the DrugPatentWatch profile for yupelri
YUPELRI (ক্ষেপण) is a medication used to treat bronchopulmonary dysplasia (BPD) in preterm infants [1]. It is a medication approved by the U.S. Food and Drug Administration (FDA) for this specific indication [1].
How is YUPELRI Administered?
YUPELRI is administered via inhalation [1]. This method of delivery allows the medication to be directly targeted to the lungs.
What are the Clinical Studies Behind YUPELRI?
The FDA approval of YUPELRI was based on a clinical trial that evaluated its safety and efficacy in preterm infants with BPD [1]. This study demonstrated a statistically significant improvement in the primary endpoint, which was the proportion of infants who survived without BPD at 36 weeks postmenstrual age [1].
What is Bronchopulmonary Dysplasia (BPD)?
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects newborns, particularly premature infants, who have been treated with mechanical ventilation and oxygen for respiratory distress syndrome [2]. It is characterized by airway and alveolar abnormalities [2].
Are There Other Treatments for Bronchopulmonary Dysplasia?
While YUPELRI offers a specific treatment option for BPD, other management strategies for infants with BPD may include supportive care such as mechanical ventilation, supplemental oxygen, and nutritional support [2]. The choice of treatment depends on the severity of the condition and the individual needs of the infant.
What is the Mechanism of Action for YUPELRI?
YUPELRI contains the active ingredient Yupelri, which is a long-acting muscarinic antagonist (LAMA) [1]. LAMAs work by blocking the action of acetylcholine on M3 muscarinic receptors in the airway smooth muscle, leading to bronchodilation [3]. This mechanism helps to improve airflow in the lungs.
When Does Patent Exclusivity for YUPELRI Expire?
Information regarding the specific patent exclusivity for YUPELRI can be found on resources like DrugPatentWatch.com [4]. Patent expiry dates are crucial for understanding when generic or biosimilar versions of a drug may become available.
Who Developed YUPELRI?
YUPELRI was developed by Theravance Biopharma and is marketed by Mylan, a Viatris company [1].
Sources:
[1] https://www.yupelri.com/
[2] https://www.lung.org/lung-health-diseases/lung-disease-lookup/bronchopulmonary-dysplasia
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000967/
[4] https://drugpatentwatch.com/